0.1%环孢素A阳离子乳剂治疗干眼病的疗效与安全性:两项双盲随机溶媒对照III期临床研究的汇总分析
汇总两项III期研究(SICCANOVE中重度干眼病、SANSIKA伴严重角膜炎的重度干眼病)数据,患者每日一次接受0.1%环孢素A阳离子乳剂(n=395)或溶媒(n=339)治疗6个月。CsA CE组CFS-OSDI应答率显著高于溶媒组(总体OR 1.66,95%CI 1.11至2.50;P=0.015),且显著降低HLA-DR表达(P=0.002)。
要点
- 总体人群中CsA CE组CFS-OSDI应答显著优于溶媒组(OR 1.66,95%CI 1.11至2.50;P=0.015)。
- 重度干眼病亚组OR 1.80(95%CI 1.04至3.19;P=0.038),伴重度干眼病的SS亚组OR 3.37(95%CI 1.20至11.19;P=0.030)。
- 总体SS人群CsA CE与溶媒差异未达统计学显著(OR 1.77,95%CI 0.89至3.66;P=0.109)。
核心结论
- 汇总III期数据表明,CsA CE在中重度干眼病患者(尤其是伴严重角膜炎者,包括伴重度干眼病的SS患者)中较溶媒显著改善体征/症状。
研究设计与样本
- 汇总分析两项相似的III期研究:SICCANOVE(中重度干眼病)和SANSIKA(伴严重角膜炎的重度干眼病)。
- 两项研究中年龄≥18岁患者接受0.1% CsA CE(n=395)或溶媒(n=339)每日一次治疗6个月。
- 采用复合应答终点CFS-OSDI(第6个月)评估疗效,应答定义为CFS改善≥2级且OSDI改善≥30%(基线至第6个月)。
- 以结膜HLA-DR表达作为眼表炎症生物标志物。
主要发现
- 总体人群中CsA CE组CFS-OSDI应答者比例显著高于溶媒组(OR 1.66,95%CI 1.11至2.50;P=0.015)。
- 重度干眼病人群中CsA CE组应答显著优于溶媒组(OR 1.80,95%CI 1.04至3.19;P=0.038)。
- 伴重度干眼病的SS人群中CsA CE组应答显著优于溶媒组(OR 3.37,95%CI 1.20至11.19;P=0.030)。
- 总体SS人群中CsA CE与溶媒差异未达统计学显著(OR 1.77,95%CI 0.89至3.66;P=0.109)。
- 第6个月CsA CE组HLA-DR表达中位数较溶媒组显著降低(P=0.002)。
关键数值与推荐
- 应答定义:CFS改善≥2级且OSDI改善≥30%(基线至第6个月)。
- 总体人群CFS-OSDI应答:OR 1.66(95%CI 1.11至2.50;P=0.015)。
- 重度干眼病亚组CFS-OSDI应答:OR 1.80(95%CI 1.04至3.19;P=0.038)。
- 伴重度干眼病的SS亚组CFS-OSDI应答:OR 3.37(95%CI 1.20至11.19;P=0.030)。
- 总体SS人群CFS-OSDI应答:OR 1.77(95%CI 0.89至3.66;P=0.109)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIM: To assess the treatment effect of 0.1% ciclosporin A cationic emulsion (CsA CE) versus vehicle on signs/symptoms of dry eye disease (DED) in various subgroups (moderate-to-severe DED/severe DED/Sjögren's syndrome (SS)/SS with severe DED). METHODS: Pooled data were analysed from two similar phase III studies: SICCANOVE (moderate-to-severe DED) and SANSIKA (severe DED with severe keratitis). In both studies, patients aged ≥18 years received CsA CE 0.1% (n=395) or vehicle (n=339) once daily for 6 months. A composite responder efficacy endpoint (corneal fluorescein staining-Ocular Surface Disease Index (CFS-OSDI) at month 6) was used to evaluate the efficacy of CsA CE in alleviating signs/symptoms of DED (response defined as improvement of ≥2 grades in CFS and ≥30% in OSDI (baseline to month 6)). Human leucocyte antigen-DR (HLA-DR) conjunctival expression was used as a biomarker of ocular surface inflammation. RESULTS: CsA CE-treated patients were significantly more likely to be CFS-OSDI responders than vehicle-treated patients in the overall (OR 1.66, 95% CI 1.11 to 2.50; P=0.015), severe DED (1.80, 1.04 to 3.19; P=0.038) and SS with severe DED (3.37, 1.20 to 11.19; P=0.030) populations. The difference was not significant for CsA CE versus vehicle for the overall Sjögren's population (OR 1.77, CI 0.89 to 3.66; P=0.109). CsA CE also significantly reduced median HLA-DR expression versus vehicle at 6 months (P=0.002). CONCLUSION: Pooled phase III data indicate CsA CE produced significant improvement in signs/symptoms versus vehicle in patients with moderate-to-severe DED (especially in those with severe keratitis), including patients with SS with severe DED.
引用
- Leonardi A, Messmer EM, Labetoulle M, et al. Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomised, vehicle-controlled phase III clinical studies. Br J Ophthalmol. 2018. PMID: 29545413. doi:10.1136/bjophthalmol-2017-311801
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。